Bicyclic peptides have greater conformational rigidity and metabolic stability than linear and monocyclic peptides and are capable of binding to challenging drug targets with antibody-like affinity and specificity.Powerful combinatorial library technologiesh ave recently been developed to rapidlys ynthesize and screen large bicyclic peptidel ibraries for ligandsa gainst enzymes,r eceptors, and protein-pro-tein interaction targets.B icyclic peptides have been developed as potential therapeuticsa gainst aw ide range of diseases, drug targeting agents, imaging/diagnostic probes, and research tools. In this Minireview,weprovide asummary of the recent progresses on the synthesis and applications of bicyclic peptides.
Introduction
The vast majority of FDA-approved drugsa re smallm olecules (M W < 500), which have the ability to modulate either extra-or intracellular targets.H owever,s mall molecules are generally limited to targeting proteins with deep binding pockets/ grooves (e.g.,e nzymes, receptors, and ion channels), which represent % 10 %o fa ll disease relevant human proteins. [1] Proteins that do not possess well defined binding pockets, such as those involved in protein-protein interactions (PPIs), are largely out of reach of small molecules. Since 1980s, an increasing number of macromolecules( M W > 5000) have arrived into the clinic. While macromolecular drugs such as antibodies are capable of binding to essentially anyt arget, they are too large to cross the cell membrane and thus limited to extracellular targets,w hich represent another % 10 %o fd isease relevant proteins. [1] This leaves the remaining % 80 %p rotein targets undruggable, including most of the proteins involved in intracellular PPIs.
The urgent demand for new drug modalities to target the undruggable proteins, coupled with the clinical success of several macrocyclic peptiden atural products (e.g.,c yclosporine A, vancomycin, and daptomycin), has inspired researchers to explore synthetic macrocyclic peptides as the next-generation therapeutics. These efforts have resulted in numerousp otent, selectivem onocyclic peptidei nhibitors against both extracellular and intracellular proteins includingm any PPI targets. [2] In general, monocyclic peptideso fs mall ring sizes (< 10 amino acids) are relatively resistantt op roteases and someh ave demonstrated oral bioavailability. [3] As the ring size increases, however,m onocyclic peptides become progressively more conformationally flexible and susceptiblet op roteolytic degradation, especially when they consist of predominantly proteinogenic amino acids. One way to improve the proteolytic stabilityo f macrocyclic peptidesi st oc onvert them into bicyclic structures, thus reducing the size of each ring to approximately half of the originals ize. The increased conformational rigidity of bicyclic peptides also further improves their target-binding affinity and selectivity.A dditionally,t he bicyclic system permitst he two rings to function independently of each other,f or exam-ple, one ring for target binding while the other for cellular entry (vide infra).Consequently,generation of synthetic bicyclic peptides with novel biological activities has been an active area of research for severald ecades. While earlier studies were limited to the development of bicyclization methods and de novo designo fb icyclic peptides, the field was greatlye nergized by the recent development of severalpowerful technologies for combinatorial synthesis of very large bicyclic peptide libraries in formats compatible with high-throughput screening for biological activity.T hese technologies have enabled researcherst oq uickly discover lead compoundst hat can either be used directly as probes of important biological functions or furtheri mproved into therapeutic agents. Thesec ompounds have also been conjugated to other drugs or biomolecules for drug targeting, diagnostic imaging or simply to enhance the properties of other therapeutic entitieswith specific pharmacokinetic deficiencies. This Minirevieww ill highlight the key developmentsi nt he preparation and application of bicyclic peptide ligandsasc hemical probesand therapeutics.
Bicyclic Peptides in Nature
Like monocyclic peptides, bicyclic peptidesa re widely distributed in nature, exhibiting diverse biological activities. [4] For example,M oroidin (1,F igure 1), is ab icyclic octapeptidei solated from the seeds of Celosia argentea, whichp revents eukaryotic cell division by inhibiting tubulin polymerization (IC 50 = 3 mm). [5] Celogentins A-K are ar elatedc lass of bicyclic octapeptides, which are also derived from C. argentea and possess antimitotic activity. [6] Amongt hese compounds, celogentin C( 2, Figure1)i sm ost potent and inhibits tubulin polymerization with an IC 50 value of 0.8 mm. [7] Other naturally occurring bicyclic peptidesi nclude phallotoxins and amatoxins, which are isolated from poisonousm ushrooms of the genus amanita. Phalloidin (3,F igure 1), the first of seven bicyclic heptapeptidyl phallotoxins isolated from the death cap mushroom( Amanita phalloides), inhibits cytokinesis and cytotaxis by preventing the depolarization of actin filaments. [8] Phalloidin binds tightly and selectively to filamentous actin (F-actin), and fluorescently labeled phalloidin has been widely used as at racer of F-actin in cells. [9] Amatoxins are bicyclic octapeptides, which exert their cytotoxicity by selectively inhibiting mammalian RNA polymerase II [LD 50 = 0.1 mg kg À1 in rats for a-amanitin (4, Figure1) ]. [10] Thep otent cytotoxicity of a-amanitin makes it an excellent "warhead" for selective tumor targeting approaches (vide infra). Finally,t heonellamides A-G are ac lass of sterol binding bicyclic peptides isolated from marine sponge, which display both cytotoxica nd antifungal activities. [11] Theonellamide F( 5,F igure 1) induces damage to cellular membranesa nd stimulates Rho1 mediated 1,3-b-d-glucan synthesis. [12] This compound also showed promising cytotoxicity against P388 and L1210 leukemia cells. [11] 3. Synthesis of Bicyclic Peptides
Rational Design
The diverse biological activities of naturallyo ccurringb icyclic peptides suggestt hat synthetic bicyclic peptides may be generated to have desirable biological activities. In 1978, Zanotti et al. reportedt he first synthesis of ab icyclic heptapeptide (6, Figure 2a ), by first formingathioether bond between ac ysteine residue and an oxidized tryptophan derivative andsubsequently headt ot ailc yclization. [13] The CD spectrumo ft he resulting heptapeptide suggested as tructural similarity to phallotoxins.M aggi et al. synthesized ab icyclic peptidyl inhibitor of the tachykinin NK2 receptor,M EN 10 627 (7,F igure 2b). [14] The linear peptides equence was synthesized on hydroxymethylbenzoic acid (HMBA) resin, with the side chains of diaminopropionic acid (Dap) and aspartate protected with Boca nd tert-butyl groups, respectively.A fter removal of the Dap and Asp sidechain protecting groups with trifluoroacetic acid (TFA), the peptidewas first cyclized on resin by forminga namide between the Dap andA sp side chains. The peptidew as then released from the resin by base hydrolysis of the ester linkage and the second head-to-tail cyclization was performed using PyBOP in dilute DMF.
Another bicyclization strategy was later reported by Tam and co-workers ( Figure 3a ). [15] Linear peptides containing two cysteiner esidues, one at the N-terminus and the other at an internal position, and aC -terminal thioester linkage wasp repared by solid-phase Boc/BOPc hemistry.F ollowing side-chain deprotection with HF,t he peptides underwent spontaneous Nto-C cyclization through an on-resini ntramolecular thioester ligation reaction and concomitant release of the peptides from the resin. Subsequent incubation in DMSO resulted in the formationo fa ni ntramolecular disulfideb ond and bicyclization of the peptides.
Because disulfide and thioether bonds have limited metabolic stability,L iskampa nd co-workersr eplaced them with alkene Curran Rhodes is currently ag raduate student pursuing his PhD degree in organic chemistry from The Ohio State University undert he direction of Dr.D ehua Pei. He receivedh is B. S. degree in biochemistryi n2 013 from OhioU niversity.A saPhD candidate,h e is also am ember of the Chemistry and Biology Interface Program( CBIP)a nd hisr esearch efforts have been directed towards the development of novel bicyclic PPI inhibitors for challenging intracellular targets. Chem. Eur.J. 2017, 23,12690 -12703 www.chemeurj.org staples by ring-closing metathesis (RCM)-mediated cyclization in preparation of ab icyclic mimic of the DE-ring system of the lantibiotic nisin ( Figure 3b ). [16] Lavilla and colleagues later expanded on this stapling approachv ia applicationo fapalladium-catalyzed CÀCb ondf ormationb etween tryptophan and iodinated tyrosine or phenylalanine( Figure 3c ). [17] Very recently,W aldmann and Grossman [18] employed orthogonal ring-closing olefin and alkyne metathesis schemes to form either manacle or butterfly shaped bicyclic peptides ( Figure 3d ). In an al-ternative approach, Grandas et al. prepared metabolically stable bicyclic peptidesv ia successive Michael addition reactions between thiols and maleimides. [19] To ensure formation of the correctb onds, one of the reactive maleimides was initially maskedw ith 2,5-dimethylfuran. Structurally diverse bicyclic peptides can be accessed with this approachbyvarying the location of the reactive groups in the linear sequence. To further expand the accessible chemical space, Reymond and colleagues [20] obtained bridged bicyclic peptides by first crosslink- ing the side chains of lysine and glutamate residues followed by thioether formation between an N-terminal chloroacetyl group and the side chain of an internal cysteine ( Figure 3e ). This method resulted in globularly shaped compounds that form intramolecular hydrogenb ond networks, mimicking bturn and a-helical structures. Bicyclic peptides have also been synthesized by simply connecting two monocyclic peptides with various linkers. [21] The above bicyclization methods have been used to optimize hit/lead peptidesi solated from combinatorial libraries. For example, startingw ith ah ead-to-tail monocyclic peptide hit (8)i solated from ap hage display library, Roodbeen et al. designed bicyclic peptide 9 as an inhibitora gainst urokinasetype plasminogen activator (uPA) (Figure 2c ). [22] They replaced the original disulfide bond with an N-to C-amide bond for the first cyclization and then introduced an ew intramoleculard isulfide bond to achieve bicyclization. Similarly,G unzberg et al. showedt hat addition of ac arbon staple to G7-18NATE (10), a selectivem onocyclic peptide inhibitor of the Grb7 SH2 domain,i ncreased the inhibitorp otencyb y2 -3 fold [e.g., K D = 1.5 mm for G7-B1 (11,F igure 2d)]. [23] Bicyclization has also been used to imposec onformational constraints on linear binding motifs. Based on ac rystal structure of vascular endothelial growth factor (VEGF) in complex with VEGF receptor-1 (VEGFR1), Inguimbert et al. [24] rationally designed ab icyclic 25mer VEGF antagonist, to mimic three of the VEGF strandsi nvolvedi nt he interaction with the receptor.I na nothere xample, rigidificationo fac itrulline-containing peptide with ap air of disulfides resulted in inhibitors with improved affinity for anti-citrullinated peptide antibodies. [25] Cell-permeable bicyclic peptides have been designed to targeti ntracellular proteins. By screening ac ombinatoriall ibrary,L ian et al. discovered ap otent monocyclic peptidei nhibitor (12,F igure 4a)a gainst protein-tyrosine phosphatase 1B (PTP1B). [26] Inhibitor 12 had poor membrane permeability,d espite containing ac ell-penetrating motif, Arg-Arg-Arg-Arg-Nal-Phe (where Nal is l-naphthylalanine), in its sequence. Interestingly,c onversion of peptide 12 into ab icyclic structure (13), in which the PTP1B-binding sequence was confined into one ring and the cell-penetrating motif in the second ring, greatlyi mprovedt he cell permeability while retaining almost full PTP1B inhibitory activity( K D = 37 nm). Peptide 13 potentiated insulin receptor signaling in HepG2 cells at nanomolar concentrations. Qian et al. recently extended this strategy to develop ag eneral methodf or intracellulard elivery of peptide ligands. [27] Briefly,a linear peptide cargo is fused to as hort CPP motif (e.g.,A rg-Arg-Arg-Arg-Nal-Phe) and the fusion peptide is bicyclized aroundasmall-molecule scaffold, 3,5-bis(mercaptomethyl)benzoic acid (BMB), by forming an amide and two disulfide bonds ( Figure 4b ). Upon cytosolice ntry,t he disulfide bonds are reduced by intracellular glutathione to releaset he biologically active linear peptidef or binding to at arget of interest. As a proof of principle, the researchers designed ab icyclic peptide (14)a sa ni nhibitor against the NEMO-IkBk inase interaction, which blockedN F-kBa ctivation in HEK293c ells via the canonical pathway.I nhibitor 14 exhibited greatly increased cellular uptake as well as serum stability compared to the linear peptide counterpart.
Chemical Synthesis of Bicyclic PeptideLibraries
Ta ma nd co-workers synthesized the first bicyclic peptide library of nine differentc ompounds by native chemical ligation and intramolecular disulfide formation. [15] To increase the odds of identifying bicyclic peptidel igands against at arget of interest, it was clear that much larger and more structurally diverse bicyclic peptide libraries must be prepared in aformat compatible with high-throughput screening protocols. Large libraries of bicyclic peptides can be readily synthesized in the one bead-onec ompound (OBOC) format with the split-and-pool methodo fL am et al. [28] However, following screening of OBOC libraries,s tructural determination of bicyclic peptide hits was not possible. To overcomet his challenge, Pei and co-workers synthesized bicyclicp eptide libraries in the one bead-two compound (OBTC) format,i nw hich each resin bead contains a unique bicyclic peptide in the surface layer but al inear peptide of identical sequence inside the bead as an encoding tag. [29, 30] Peptide cyclizationw as mediated by the formation of three amide bonds between arigid small-molecule scaffold, trimesic acid (TMA), and the N-terminal amine and the side chains of an internal lysine residue and aC -terminal Dap residue of the peptide (Figure 5a ). During library screening against ap rotein target of interest, the protein only has access to the bicyclic peptides on the bead surfacea nd the linear peptides inside the beads do not interfere with library screening.O nce an active hit(s) is identified, its structure is readily determined by sequencing the linear peptide tags inside the bead(s) by using Edman degradation and/orm ass spectrometric methods. [31] This methodi shighly versatile, capable of generating bicyclic peptides of different ring sizes and peptides equences, and is compatible with both natural and unnatural amino acids (e.g., d-amino acids) as well as nonpeptidic moietiesa s buildingb locks. For example, Lian et al. [30] synthesized ab icyclic peptidel ibrary containing 3-5 random residues in each ring and 24 different l-a nd d-aminoa cids (Figure 5a ), which has at heoretical diversity of 1.0 10 14 ,a lthough in practice the size of OBTC libraries is limited to 10 8 different compounds. Screening of the libraryi dentified ab icyclic peptidea ntagonist of TNF-a (15,F igure 5b)w hichi nhibited TNF-a from binding to its cognate receptor in ac oncentration-dependent manner (IC 50 = 3.1 mm). [30] To obtain cell-permeable macrocyclic peptide ligandsagainst intracellular targets directly from combinatorial libraries, Trinh et al. modified the OBTC bicycle library design so that one ring consisted of different peptides equences forp otential binding to at arget of interest, while the second ring featured aC PP motif (Phe-Nal-Arg-Arg-Arg-Arg or Arg-Arg-Arg-Arg-Nal-Phe) for cellular entry. [32] This library was screened for in vitro binding to an oncogenicK -Ras mutant (G12V), ad river for many human cancers. Remarkably,a ll of the library hits were cell-permeable, suggesting that the bicyclic design offersageneral approach to developing macrocyclicpeptides against intracellular targets.O ne of the bicyclic peptidyl Ras inhibitors (16,F igure 5c)p hysically blocked the Ras-Raf interaction with an IC 50 of 3.4 mm,i nhibited Ras signaling in cell culture, and induced apoptosis of human cancer cells at low mm concentrations. [32] 
Biological SynthesisofB icyclic Peptide Libraries
Bicyclic peptides have also been produced biologically via ribosomals ynthesis, which is capable of generating libraries of enormousd iversity (up to 10 14 different compounds). Heinis and Winter pioneered the biological synthesis of bicyclic peptides by phage display. [33] They first generated al inear peptide libraryo ft he sequence C-X 6 -C-X 6 -C (where Ci sc ysteinea nd X is any of the 20 proteinogenic amino acids) on the surface of filamentous phage, using the methodo fS mith. [34] The linear peptides were then converted into bicyclic peptides by reacting the peptidesw ithas mall-molecule scaffold, tris(bromomethyl)benzene( TBMB), whichs electively alkylated the three cysteine residues in the sequence (Figure 6a ). The effectiveness of this approachw as demonstratedb yi solation of potent bicyclic peptidei nhibitors against proteases plasma kallikrein and cathepsin[ K I values of 2.9 and 100 nm,r espectively].I na ddition to TBMB,o ther small-molecule scaffolds such as 1,3,5-triacryoyl-1,3,5-triazinane (TATA), N,N',N''-(benzene-1,3,5-triyl)tris(2-bromoacetamide) (TBAB),a nd N,N',N''-benzene-1,3,5-triyltrisprop-2-enamide have also been used to generate bicyclic peptides of different ring sizes and flexibility. [35] Alternatively,p hage displayed bicyclic peptides can be formed via two disulfide bonds. To preventt he formation of am ixture of different disulfide bridges,H einis and co-workers designedd i-thiol amino acids (DTaas). [36] Incorporation of one of these unnatural amino acids into as equence containing two cysteine residues followed by oxidation produced asinglebis-disulfide bicyclic species ( Figure 6b ). This method has not yet been widely adopted, presumably because of the relative lability of the disulfide bonds.
Another method for ribosomal synthesis of bicyclic peptides is mRNA display.I nc onventional mRNA display,e ach linear peptidei sc ovalently linked to its encoding mRNA through the use of antibiotic puromycin and the identity of ah it peptidei s determined by reverset ranscription of the mRNA and sequencing the resulting cDNA (Figure 7a ). [37] Suga and co-workersm odified the mRNA display protocol by reprogrammingt he geneticc ode to incorporate unnatural amino acids. For example, they incorporated af ixed cysteineat the N-terminus of ap eptide sequence and re-assigned the Phe codon (UUC) at an internal position to 4-(2-chloroacetyl)aminobutyric acid (Cab);t he resulting newly translated peptideu nderwents pontaneous cyclization by forming at hioether linkage between the N-terminal cysteinea nd the Cab residue (Fig-ure 7b ). [38] Bicyclizationw as achieved by additionally incorporating azidohomoalaninea nd propargyl glycine residues into the peptides equence, followed by Cu I -mediated azide-alkyne cycloaddition.M ore recently,H acker et al. exploited the orthogonality between alkylation of cysteines ide chains with bis(bromomethyl)benzene and click chemistry to produce bicyclic peptides that are either mannacle shaped or theta-bridged (Figure 7c ). [39] Unlike previous bicyclic peptidel ibraries, in which the conformation of bicyclic peptides was pre-determined by the small-molecule scaffold, the bicyclization methodo fH ackere tal. is scaffold free, therefore allowing for different loop attachment points and access to multiple bicyclic topologies.
Fasan and co-workers have adapteda ni ntein splicing strategy,t ermed" split-intein circular ligationo fp eptides and proteins (SICLOPPS)", [40] to generate bicyclic peptidel ibraries. [41] Inteins are self-excising protein domains that process to link their flanking sequences by an ative peptideb ond. [42] AS I-CLOPPSc onstruct consists of the C-terminal fragment of an intein (INT C ), ap eptides equence to be cyclized, and the N-terminal fragment of the intein (INT N ) ( Figure 7d ). Upon transcription and translation,t he N-and C-terminal intein fragments reassemble to form an active intein,w hich subsequently cyclizes the peptides equence of interest through peptides plicing. [43] By integrating the SICLOPPS method with genetici ncorporation of unnatural amino acids, Bionda and Fasan prepared natural product-like bicyclic peptides of varying ring sizes and intramolecular connectivity patterns. [41] The initial N-to-C macrocyclization was achieved by protein splicing using the split intein of DnaE, while furtherc yclization to form the bicycle was effected by thioether formation between the side chains of ag enetically encoded O-(2-bromoethyl)-tyrosine and ac ysteine residue. Future integration of this methodw ith one of the peptided isplay techniques may allow access to combinatorial libraries of natural product-like bicyclic peptides that can be screened against at arget of interest.
Among the methodsd escribed for bicyclic peptide library synthesis, the OBTC method is most versatile with respectt o the nature of buildingb locks and the chemical reactions employed to connect the building blocks, producings tructurally diverse, metabolically stable, and naturalp roduct-like bicyclic peptides. Its main disadvantage is that the library size is currently limited to % 10 8 different compounds, although this size limit can be increased by % 1000-fold by synthesizing DNA-encoded OBTC libraries. [44] So far,b icyclic PPI inhibitors derived from naïve OBTC libraries have typically exhibited high nm to low mm bindinga ffinities to the intended targetsa nd usually requiref urthero ptimization by either conventional medicinal chemistry approaches or synthesis and screening of secondgeneration libraries (biasedl ibraries). On the other hand, mRNA display libraries canr each 10 14 in diversity and, as a result, highly potent ligands( with pm to low nm K D values) can often be directly isolated from such libraries. mRNA displayl ibrariesa re, of course, limited to buildingb locks that are recognizable by the ribosome, namely proteinogenic amino acids and as ubset of unnatural amino acids (e.g.,N a -methylated lamino acids). [45] Phage-display and SICLOPPS libraries have an 
Applications of Bicyclic Peptides

Therapeutics and Chemical Probes
Enzyme Inhibitors
An umber of naturally occurring bicyclic peptides have been used as therapeuticsa nd/orr esearch tools. For example, romidepsin (17,F igure 8) is as mallb icyclic depsipeptide derived from the bacterium Chromobacterium violaceum and ap otent histoned eacetylase inhibitor. It has received FDA approval for treatment of cutaneous T-cell lymphoma and other peripheral T-cell lymphomas. [46] Another naturally occurring bicyclic peptide, bouvardin,i satranslation inhibitor which has been patented for use as an anticancer agent,i nc ombination with radiation therapy or other chemotherapeutic agents. [47] As mentioned previously, a-amanitin (4,F igure 1) is ab icyclic peptidyl toxin that potently inducesa poptosis of both rapidlyd ividing and slowly growingc ells. To reduce its toxicity,s cientists at Heidelberg Pharmaceuticals conjugated it to at umor targeting antibody. [48] The resulting antibody-drug conjugate (ADC) has shown promise for the treatment of drug-resistantt umors.F or example, conjugation of a-amanitin to an antibody against prostate-specific membrane antigen (PSMA) resulted in complete tumor remission in ap rostate cancerm ice modela ta 150 mgkg À1 dose. In addition, because a-amanitin is highly water soluble, even at ar elatively high drug loading, the ADC did not suffer from aggregation problemst hat are frequently encountered with small-molecule ADC's.
The success of biologically active bicyclic peptides from natureh as inspired chemists to explore synthetic bicyclic peptides as therapeutic agents and research tools. Bicyclic peptides have been found to be highly effective enzyme inhibitors, especially against extracellular enzymes,s ince in the latter case, membrane permeation is not required. Bowman-Birki nhibitors (BBI) are small, disulfide-rich protein inhibitors of serine proteases which have shown promise for treatmento f musculara trophy,c ancera nd neurodegenerative, inflammatory,a nd cardiovascular diseases. [49] Ando et al. synthesized ab icyclic hexadecapeptide corresponding to the chymotrypsinbinding site of the soybean BBI (18,F igure 8), as ap roteolytically stable ande ffective inhibitor of chymotrypsin. [50] Heinis and others screened phage displayed bicyclicp eptide libraries against severalp roteases and discovered highly potent and specific inhibitors against both plasma kallikrein (PK) and urokinase-type plasminogen activator (uPA). [51] For example, UK18 showed > 2000-fold selectivity for uPAr elative to closely related proteases.O ther efforts produced ab icyclic peptidei nhibitor with a K I value of 8.1 nm against the coagulation factor [36] c) bicyclization of mRNA displayed peptidelibrarybyt he methodofH ackeretal.; [37] and d) bicyclizationofS ICLOPPS-synthesized peptides by the method of Bionda andFusan. [39] XII. [52] Synthesis and testingo fs everald ozen analogs led to bicyclic peptide 19 (Figure 8) , which showed a1 0-fold higher target-binding affinity and a % 5-fold increasei nb lood plasma half-life. [53] As discussed previously,L ian et al. engineeredc ellpermeable bicyclic peptidyli nhibitors against intracellular enzymes PTP1B and peptidyl-prolyl cis-trans isomerase Pin1, by fusing monocyclic peptide inhibitors previously identified from OBTC libraries with ac yclic CPP. [26] The bicyclic peptidyl PTP1B inhibitor( 13,F igure 4) showedb oth high potency (K D = 37 nm) and selectivity for PTP1B (17-foldl ower potencyf or the closely related TCPTP and no inhibition of any of the other PTPs tested). The bicyclic PTP1B inhibitor provides ap otentiall ead for further development of treatment for type II diabetes. Pin1 is dispensablei nn ormalc ellsb ut is overexpressed in many cancersa nd required for cancerc ell proliferation, suggesting that Pin1 inhibitors may have applications as anticancer agents. [54] The bicyclic peptidyl Pin1 inhibitor of Lian et al. (20, Figure 8 ) inhibited the intracellular function of Pin1 and the proliferation of HeLa cells. [26] The group later reported an improveda nalogue of peptide 20,w hich is non-phosphorylated and metabolically more stable. [55] Bicyclic peptides are capable of achieving exquisite specificity for ag iven enzyme, because their large sizes allow them to interactw ith not only the active site, buta lso the less conservedr egions surrounding the active site. In addition to therapeutica pplications, highly selective enzymei nhibitors also provide powerful tools for chemical biology, allowing researchers to specifically "knockout" the activity of ag iven enzymei nacomplex system with temporal controla nd assess the biological function of the enzyme in an otherwise native system.
PPI Inhibitors
One of the main impetuses for developing macrocyclic peptides is to inhibitP PIs, which are challenging targets for conventional drug modalities. Severalb icyclic peptide PPI inhibitors have been rationally designedf rom their linear or monocyclic peptidep recursors. For example, the Bcl2 homology (BH) proteins are well validated anticancer drug targets that regulate apoptosis by influencing mitochondrial outer membrane permeabilization (MOMP). Fairlie and colleagues showedt hat bicyclization of ap reviously reportedB AD BH3 peptide resulted in shorter (8-14 AA's), more potent, and more drug-like peptidomimetics against Bcl-xL (21, Figure 9 ). [56] Grb2 is ak ey adaptor protein involved in receptor tyrosine kinase signaling pathways, by binding to specific phosphotyrosyl residues on the receptors via its SH2 domain. [57] Grb2 inhibitors thus have therapeutic applicationsa sa nticancer agents. Quartararo et al. designed ab icyclic peptide inhibitor of the Grb2 SH2 domain. [58] They found that conversion of am onocy- Chem. Eur.J. 2017, 23,12690 -12703 www.chemeurj.org clic undecapeptide, G1, into ab icyclic peptide, BC1 (22, Figure 9 ), resulted in 60-fold higherp otency and 200-fold improvedselectivity for the Grb2 SH2 domain. In another application, dimerizationo fapotent monocyclic peptidei nhibitor produced an effective bicyclic peptidet herapeutic against vascular endothelial growth factor (VEGF). [59] Other investigators have discovered bicyclic peptide PPI inhibitors against several notable therapeutic targets from combinatorial libraries.L ian et al. screened an OBTC library of 3 10 5 bicyclic peptides against human TNFa and discovered two hits which prevented TNFa from binding to its cognater eceptors and protected cells against TNFa-induced death [IC 50 = 3.1 mm for anticachexinC1 (15, Figure 5b) ]. [30] Protein inhibitors against TNFa (e.g.,H umira) are among the top-sellingd rugs for treatment of ar ange of inflammatory diseases. Metabolically stable bicyclic peptideT NFa inhibitors mayp rovidealowercost, less immunogenic, and potentially orallya ctive replacement for the protein inhibitors. Screening of the same library against oncogenic K-Ras G12V identified two different types of K-Ras ligands. [60] The first type [e.g.,c yclorasin B3 (23, Figure 9 ); K D = 2.1 mm]a pparently bind to K-Ras at or neart he effector-binding site and inhibited the Ras-Raf interaction in vitro, while the second type of ligands bind at an yet undetermined site and do not affect effector binding. Unfortunately, these hits showedn os ignificant anticancer activity because of poor membrane permeability.T rinh et al. later modified the library design by incorporating aC PP sequence into one of the rings. [32] Screening of this library against K-Ras G12V followed by hit optimization produced bicyclic peptide 16 (Figure 5c ), which was cell-permeable, inhibited K-Ras signaling in cell culture, and induceda poptosis in lung cancerc ells (LD 50 % 17 mm). Mund et al. identified several bicyclic peptides that prevented ubiquitination of the Smurf2H ECT domain, by screening ap hage-displayed library. [61] The mostp otent compound( 24,F igure 9) had an IC 50 of 2.5 mm and excellent selectivity for the Smurf2 HECT domain, enabling its use as ap robe during subsequent screening of small-molecule inhibitors. As described previously,adisulfide-mediated bicyclic peptidei nhibitor against the NEMO-IKK interaction has been developed for potential treatmento fi nflammation andc ancer. [27] 
Receptor Agonists and Antagonists
Af ew bicyclic peptides have been reported as agonists or antagonists of cell surfacer eceptors, most of which are natural products or derived from rational design efforts. BI-32169 (25, Figure 10 ), a1 9-aa bicyclic peptidei solated from Streptomyces sp. (DSM 14996), is am oderately potent antagonist against the human glucagon receptor (IC 50 440 nm)i naf unctional cellbased assay. [62] In addition to the synthetic NK2 receptor antagonist (7)d escribed previously (Figure 2b ), Hruby and co-workers synthesized ab icyclic peptidea nalog of oxytocin, 4,8-cyclo[Mpa 1 ,Glu 4 ,Cys 6 ,Lys 8 ]oxytocin. [63] This bicyclic peptide acts as av ery potent antagonist of oxytocin in the rat uterus assay with an in vitro pA 2 value of 8.2 andapA 2 value of 6.45 in vivo. Discovery of agonists or antagonists from combinatorial libraries has been challenging, because library screening requires the availability of the receptor protein in purified forms, Chem. Eur.J. 2017, 23,12690 -12703 www.chemeurj.org which is generally difficult for integral membrane proteins. Heinis and colleagues screened phage displayed bicyclic peptide libraries against the soluble extracellulard omains (ECDs) of the epidermal growth factor receptor Her2 and the Notch receptor. [64, 65] Although relatively potent and selective ligands were identified for both ECDs (K D of 304 and 150 nm,r espectively),n either ligand showeda gonisto ra ntagonist activity against the respective receptor signaling. Presumably,t he bicyclic peptides bound to the ECDs at functionally unimportant sites. These peptide ligands may,h owever,o ffer valuable starting points for the development of high-affinity receptor binders with potential application for tumori maging and therapy (vide infra).
Drug Targeting
Antibody-drug conjugates (ADC's) have become ap opulara pproach to improvingt he therapeutic windowo fs mall-molecule drugs. [66] Typically,ahighly potent small-molecule drug is covalently attached to am onoclonal antibodys pecific for an antigen unique to or over-expressed on at arget tissue( e.g.,a tumor). Binding of the antibody to the antigen results in concentration of the ADC to the target tissue. However,A DC's suffer from several drawbacks, including low drug payload per unit mass of antibody,h igh cost of production,a nd most significantly, poor tissue penetration (e.g.,s olidt umors) due to the large size of antibodies. Since bicyclic peptides are capable of binding to diversep rotein targets with antibody-likeb inding affinity and specificity but are much smaller is size, they are ideally suited as drug-targeting agents. In fact, bicyclic peptide-drug conjugates (BDC's) have become the platform technologya tB icycle Therapeutics (Cambridge, MA), fors elective delivery of chemotherapeutic agents or other drugs to target cell populations. The smalls ize of BDC'sa llows them to penetrate deeply into solid tumors, while retaining high renal clearance to reduce drug-induced toxicity.I nc ollaborationw ithA s-traZeneca, Bicycle Therapeuticsi sd eveloping BDCs for the treatment of cancera sw ell as respiratory,c ardiovascular and metabolic diseases. Their most promising lead compound, BT1718,aconjugate targeting membrane type-1 matrix metalloproteinase (MT1-MMP) fors olid tumors,h as passed GLP toxicology testing and is expected to enter clinical trials within the year. [67] BDC'su tilizing the tumor targeting ability of RGD peptides have also been developed. For example, ap rodrug intendedt os pecifically target tumors over-expressing integrins a v b 3 and a v b 5 was synthesized by covalently attaching doxorubicin to ab is(disulfide)-mediated bicyclic RGD peptide( 26, Figure 11 ). [68] Ap eptides equence recognized by tumor specific plasmin protease was used as al inker to further improvet umor selectivity.T he BDC showedp lasmin-dependent cytotoxicity to cancer cells in vitro, although diminished binding affinity and poor solubility of the conjugate have limited itse ffectiveness in vivo. In another example, conjugation of the microtubulin inhibitor paclitaxel to ab icyclic RGD peptidea llowed its selective delivery to integrin a v b 3 -expressing tumors. [69] These initial successes clearly demonstrate that BDC'sc an be developeda s viable (ands uperior) replacements of ADC's.
Imaging and Diagnostics
Bicyclic peptides are very attractive as PET tracers and other diagnostic imaging agents. Compared to monoclonal antibodies and other protein binders, bicyclic peptides have much faster clearance, due to their smaller sizes, resulting in excellent www.chemeurj.org signal-to-background ratios and shorter delays between dosing and imaging. The discovery of five somatostatinr eceptor subtypes (sst1-sst5) that are differentially over-expressed on the surfaceo fd ifferent cancerc ells led researchers to explore radiolabeled somatostatin derived bicyclic peptides for imaging applications. Researchers at Merck first developed bicyclic somatostatinanaloguest oi mprovethe metabolic stability of the natural hormone, somatostatin-14 (SRIF-14). [70] Further investigationb yF alb et al. revealed that conformationally constrained bicyclic analogues of somatostatinc ould target specific sst receptor subtypes. [71] Based on these findings,F ani et al. designed ab icyclic somatostatina nalog conjugatedt o 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) doped with either 177 Lu or 68 Ga for potential use for sst receptor subtypet argeting in diagnostic imaging. [72] The high clearance rate of the most promisingc ompound, 68 Ga-AM3 (27, Figure 12 ), from non-targeted tissues resultedi nh ight umorto-blood and tumor-to-muscle ratios after only 1h,w hich may permiti ts application in PET or CT studies of sst-positive tumors.H owever,p oor internalization led to rapid washout from sst positive tumors,p reventing their use with more longlived radionuclides for therapeutic purposes.I na nother example, am onocyclic RGD peptidew as further rigidified by incorporation of aminocyclopentane (ACP) or aminocyclohexane (ACH) as residue side chains. [73] Conjugation of the resulting bicyclic peptidetoDOTAloaded with 64 Cu generated an effective PET imaging agent.T he conjugate (28,F igure 12) showed higher affinity for U87MG glioblastoma cellst han their monocyclic counterparts and was able to efficiently localize to integrin positive tumors.L astly, as mentioned previously,f luorescently labeled phalloidin (3,F igure 1) has also been widely used as at ool to visualize actin filaments in cellular studies. [9] 
Summary and Outlook
Since 2009, there has been ar apid growth in the discovery and applications of bicyclic peptide ligands against enzymes, receptors, and PPI targets, thanks to the advent of several powerful combinatorial library technologies. It is now feasible to develop bicyclic peptides with antibody-like affinity and specificity form any (if not all) proteins. In the coming years, we anticipate that many of the traditional roles of antibodies (e.g.,t herapeutics, diagnostics, and research tools) will be playedb yb icyclic peptides (or other macrocyclic compounds), because the latter have better cell and tissuep enetration, greaterm etabolics tability,a nd lower cost of production. Perhaps the moste xciting application of bicyclic peptides will likely be their use as inhibitors of intracellular PPIs which are, as of date, largely out of reach of small molecules or antibodies. The remaining challenges will be how to selectively deliver the bicyclic peptides to diseasedt issues and/or effectively deliver them into the cytosol (and the nucleus) of mammalian cells.
